Sep 03, 2019 PRESS RELEASES Comments Off on Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
LÖRRACH, Germany and SAINT-LOUIS, France, Sept. 03, 2019 (GLOBE NEWSWIRE) — Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant infections, today announced four upcoming presentations at the ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, taking place September 3-6 in Boston, MA at the Boston Park Plaza. The company and its collaborators will deliver presentations on its lead drug enmetazobactam (formerly AAI101), a potent extended-spectrum β-lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime is currently in late stage of a global Phase 3 development for the treatment of complicated urinary tract infections, including acute pyelonephritis, by Gram-negative bacteria.
“We are excited to share data from four posters at ASM/ESCMID this year. Each of these presentations adds to the growing body of evidence in favor of cefepime-enmetazobactam to treat infections by third-generation cephalosporin (3GC)-resistant Enterobacteriaceae, the most prevalent ‘critical priority’ pathogen as defined by the WHO,” said Klaus Wilgenbus, Chief Executive Officer of Allecra Therapeutics. “These presentations underline our ongoing commitment to make Allecra’s data accessible to practicing physicians.” Third-generation cephalosporin resistance is frequently encountered in Gram-negative hospital pathogens and is mainly mediated by ESBLs. Cefepime-enmetazobactam is intended as an empiric carbapenem-sparing option for the treatment of serious Gram-negative infections in settings where ESBLs are prevalent.
Details for the poster presentations at ASM/ESCMID 2019 are as follows
About Allecra Therapeutics
Allecra Therapeutics, established in 2013, is a clinical-stage biopharmaceutical company contributing towards the global effort to combat antibiotic resistance by developing new therapeutic modalities to overcome emergent resistance mechanisms, thereby saving lives of patients whose infections may otherwise be treated inadequately.
Allecra’s lead product enmetazobactam (formerly AAI101), in combination with the 4th generation cephalosporin cefepime, is being developed for empiric use in complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired bacterial pneumonia/ventilator-
Allecra is supported by Forbion, Delos Capital, Andera Partners, formerly EdRIP, Xeraya Capital, EMBL Ventures, and BioMed Partners. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from the French public bank Bpifrance and from the Région Alsace.
Comments Off on Taiwan expected to report further export fall for August
Comments Off on Solomon Islands hopes decision on ties with Taiwan by Sept. 21
Comments Off on Taiwan national fined heavily for bringing in pork products
Comments Off on Philips Global Beauty Index reveals that women want personalized beauty solutions to meet their unique needs
Comments Off on The Boiling Crab Announces Second International Licensing Agreement
Comments Off on BitHarp Launches the Most Profitable Mining Rigs in the Market